New leadership to drive growth in TIDES
Dr Matteo Villain.

Company news

New leadership to drive growth in TIDES

17 Aug, 2025

Veranova has appointed Dr Matteo Villain as Vice President of Peptides and Oligonucleotides, strengthening its presence in the TIDES (peptides and oligonucleotides) sector.

Dr Villain brings extensive experience across the development and manufacturing lifecycle of peptide APIs, including process development, scale-up, cGMP production, validation, and regulatory compliance. He has led the development of over 60 peptide APIs and held senior leadership roles at Bachem Americas, Inc, including VP of Research and Development, VP of GMP Manufacturing, and VP of CMC Development. More recently, he served as Vice President and Global Peptides Technical Lead at Piramal Pharma Solutions and founded MV API Consulting.

“Dr Villain’s holistic expertise in peptide API development and manufacturing will be a tremendous asset to Veranova,” said Rohtash Kumar, Senior VP of Development Operations and Chief Technology Officer. “This strategic hire supports our ongoing investments in bioconjugation, HPAPI, and ADC expansion, helping us advance our initiatives in the TIDES space.”

Dr Villain holds a Doctorate in Medicinal Chemistry and Pharmaceutical Science from the University of Milan and completed postdoctoral fellowships at The University of Alabama (Birmingham) and the University of Geneva. He has shared his expertise at industry events including Tides USA and US Pharmacopeia (USP) workshops.

More information online

Latest News

Lab Asia 33.4 - August 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
England's rivers and lakes: what the 2025 data really shows about pollution drivers
Explore more Arrow
Pollution Solutions Online
Leading UK biogas operator places first orders for new FlowSep technology
Explore more Arrow
Petro Online
A single supplier, eight failures: Indonesia's flashpoint problem
Explore more Arrow
Chromatography Today
LC–MS/MS metabolite panel shows potential for breast cancer assessment
Explore more Arrow